CLEVELAND, July 10, 2019 /PRNewswire/ -- Centerline Biomedical, Inc. (Centerline) has announced that the company has received 510(k) clearance from the United States Food and Drug Administration (FDA) to market its flagship product, the Intra-Operative Positioning System, IOPS.
A non-radiation-based surgical navigation system for minimally invasive surgery, IOPS leverages anatomical mapping algorithms and electromagnetic tracking technology to provide three-dimensional color visualization and guidance in real time during endovascular procedures. The system, developed at Cleveland Clinic's Heart and Vascular Institute, addresses the need for a path away from X-ray fluoroscopy which is currently the standard of care, despite severe visualization challenges.
Story Continues Below Advertisement
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
"To date, Cleveland Clinic has partnered with some 87 companies; among these, Centerline has been particularly rewarding and we are very excited about them having received 510(k) clearance. Most certainly as partners, shareholders, and prospective customers, we at Cleveland Clinic look forward to continuing support of the exciting research and commercialization efforts of this rapidly growing company," stated Jim Zalar, General Manager of Business Solutions at Cleveland Clinic Innovations and Cleveland Clinic's appointee to the company's Board of Directors.
Once in the market, Centerline hopes to show significant value to the technology by reducing procedure cost while improving radiation safety and patient outcomes. "Having worked closely with Centerline for almost five years, I am very pleased to see that IOPS will soon be commercially available," remarked Dr. Matthew Eagleton, Chief of Vascular Surgery at Massachusetts General Hospital and Chair of the company's Scientific Advisory Board. "We hope to use this game-changing technology to revolutionize our approach to vascular procedures and imaging."
This milestone, achieved working with regulatory partner JALEX Medical, will allow marketing and commercial use of IOPS for endovascular interventions in the descending aorta, though the underlying platform will be applicable to many other minimally invasive procedures in the future. Such future indications may include structural heart interventions, an application the company is currently exploring with funding from an NIH small business grant. The company's R&D efforts will continue in parallel with Centerline's upcoming market launch.
SOURCE Centerline Biomedical